IP Library Granted Patent US 8,273,360
Granted Patent B2
US 8,273,360 · App. 10/181,600 · Granted Sep 25, 2012

Outer membrane vesicle (OMV) vaccine comprising

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,273,360
App. No.
10/181,600
Granted
Sep 25, 2012
Kind
B2
Abstract

A composition comprising (a) Neisseria meningitidis serogroup B outer membrane vesicles (OMVs), and (b) an immunogenic component selected from other Neisseria proteins, or immunogenic fragments thereof. Component (b) preferably includes a protein from a different NmB strain from that from which the OMV of component (a) is derived. The OMVs are preferably obtained by deoxycholate extraction. Optionally, the composition may also comprise a protective antigen against other pathogens.

Claims (29)

1. A composition comprising a Neisseria meningitidis serogroup B outer membrane preparation mixed with a purified m741.pep protein comprising the amino acid sequence of SEQ ID NO: 22 or an immunogenic fragment of the m741.pep protein comprising ten or more consecutive amino acids of the amino acid sequence of SEQ ID NO: 22.

2. The composition of claim 1 , wherein the protein, the Neisseria meningitidis serogroup B outer membrane preparation, or both are adsorbed on Al(OH) 3 .

3. The composition of claim 1 , wherein the outer membrane preparation comprises outer membrane vesicles (OMVs) of the Neisseria meningitidis serogroup B.

4. The composition of claim 3 , wherein the OMVs are a deoxycholate extract from the Neisseria meningitidis serogroup B.

5. The composition of claim 2 , wherein the protein is adsorbed on Al(OH) 3 .

6. The composition of claim 1 , further comprising an isolated or purified Neisseria meningitidis protein selected from the group consisting of:

(a) protein ORF1 comprising the amino acid sequence of SEQ ID NO: 16;

(b) protein ORF40 comprising the amino acid sequence of SEQ ID NO: 17;

(c) protein ORF46 comprising the amino acid sequence of SEQ ID NO: 18;

(d) protein 287 comprising the amino acid sequence of SEQ ID NO: 19;

(e) protein 919 comprising the amino acid sequence of SEQ ID NO: 21 and

(f) transferrin binding protein B (TbpB) comprising the amino acid sequence of SEQ ID NO: 15.

7. The composition of claim 6 , comprising the protein ORF1 comprising the amino acid sequence of SEQ ID NO: 16.

8. The composition of claim 6 , comprising the protein ORF40 comprising the amino acid sequence of SEQ ID NO: 17.

9. The composition of claim 6 , comprising the protein ORF46 comprising the amino acid sequence of SEQ ID NO: 18.

10. The composition of claim 6 , comprising the protein 287 comprising the amino acid sequence of SEQ ID NO: 19.

11. The composition of claim 6 , comprising the protein 919 comprising the amino acid sequence of SEQ ID NO: 21.

12. The composition of claim 6 , comprising the TbpB comprising the amino acid sequence of SEQ ID NO: 15.

13. A composition comprising a Neisseria meningitidis serogroup B outer membrane preparation isolated from a recombinant serogroup B Neisseria meningitidis that hyperproduces a protein from a strain of Neisseria meningitidis serogroup B different from the recombinant serogroup B Neisseria meningitidis and wherein the protein is m741.pep comprising the amino acid sequence of SEQ ID NO: 22 or an immunogenic fragment of the m741.pep protein comprising ten or more consecutive amino acids of the amino acid sequence of SEQ ID NO: 22.

14. The composition of claim 13 , wherein the outer membrane preparation comprises outer membrane vesicles (OMVs) of the Neisseria meningitidis serogroup B.

15. The composition of claim 14 , wherein the OMVs are an isolated deoxycholate extract from the recombinant Neisseria meningitidis serogroup B.

16. The composition of claim 13 , wherein the Neisseria meningitidis serogroup B outer membrane preparation is adsorbed on Al(OH) 3 .

17. The composition of claim 13 , further comprising an isolated or purified Neisseria meningitidis protein selected from the group consisting of:

(a) protein ORF1 comprising the amino acid sequence of SEQ ID NO: 16;

(b) protein ORF40 comprising the amino acid sequence of SEQ ID NO: 17;

(c) protein ORF46 comprising the amino acid sequence of SEQ ID NO: 18;

(d) protein 287 comprising the amino acid sequence of SEQ ID NO: 19;

(e) protein 919 comprising the amino acid sequence of SEQ ID NO: 21 and

(f) transferrin binding protein B (TbpB) comprising the amino acid sequence of SEQ ID NO: 15.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 23, 2015
From: NOVARTIS AG
To: GLAXOSMITHKLINE BIOLOGICALS SA
Reel/Frame 035231/0253 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2015
From: NOVARTIS AG
To: GLAXOSMITHKLINE BIOLOGICALS SA
Reel/Frame 035219/0598 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 1, 2008
From: NOVARTIS VACCINES AND DIAGNOSTICS SRL
To: NOVARTIS AG
Reel/Frame 021904/0964 →
CHANGE OF NAME Recorded Nov 21, 2008
From: CHIRON SRL
To: NOVARTIS VACCINES AND DIAGNOSTICS SRL
Reel/Frame 021901/0111 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2004
From: PIZZA, MARIAGRAZIA; RAPPUOLI, RINO; GIULLANI, MARZIA MONICA
To: CHIRON S.R.L.
Reel/Frame 015240/0456 →